Get the Stockscreener App
22.47
2.52%
-0.58
After Hours:
22.47
Nurix Therapeutics Inc stock is traded at $22.47, with a volume of 796.98K.
It is down -2.52% in the last 24 hours and down -10.83% over the past month.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
See More
Previous Close:
$23.05
Open:
$22.83
24h Volume:
796.98K
Relative Volume:
1.16
Market Cap:
$1.46B
Revenue:
$80.89M
Net Income/Loss:
$-144.73M
P/E Ratio:
-7.5657
EPS:
-2.97
Net Cash Flow:
$-83.87M
1W Performance:
-6.76%
1M Performance:
-10.83%
6M Performance:
+52.86%
1Y Performance:
+185.88%
1-Day Range:
$22.14
$24.00
1-Week Range:
$22.14
$24.50
52-Week Range:
$4.22
$26.31
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Name
Nurix Therapeutics Inc
Sector
Industry
Phone
(415) 660-5320
Address
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-24 | Initiated | Truist | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-09-23 | Initiated | Barclays | Overweight |
| Feb-28-23 | Initiated | Oppenheimer | Outperform |
| Oct-11-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Dec-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-30-21 | Resumed | Piper Sandler | Overweight |
| Apr-30-21 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Nov-19-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | Stifel | Buy |
View All
Nurix Therapeutics Inc Stock (NRIX) Latest News
Nurix Therapeutics Announces Presentations at Discovery on Target Conference - GlobeNewswire
Nurix Therapeutics Announces Presentations at Discovery on Target Conference - StockTitan
Nurix Therapeutics's SWOT analysis: biotech stock's potential in BTK degraders - Investing.com
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Position Lessened by Ensign Peak Advisors Inc - Defense World
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Position Lessened by Ensign Peak Advisors Inc - MarketBeat
Driehaus Capital Management LLC Takes $26.78 Million Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Fred Alger Management LLC Acquires New Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
XTX Topco Ltd Lowers Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Renaissance Technologies LLC Purchases 144,700 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Affinity Asset Advisors LLC Buys 101,747 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Affinity Asset Advisors LLC Has $19.03 Million Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Samlyn Capital LLC Invests $12.18 Million in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Stock Market Recap: Nurix Therapeutics Inc (NRIX) Concludes at 24.10, a -5.93 Surge/Decline - The Dwinnex
Robert W. Baird gives an Outperform recommendation for Nurix Therapeutics Inc (NRIX) - Knox Daily
Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase - Benzinga
Farallon Capital Management LLC Acquires New Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Samlyn Capital LLC Takes $12.18 Million Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Trading Down 5.7% - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Trading Down 5.7% - Defense World
Integral Health Asset Management LLC Buys New Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Massachusetts Financial Services Co. MA Sells 14,608 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
First Week of November 15th Options Trading For Nurix Therapeutics (NRIX) - Nasdaq
Integral Health Asset Management LLC Buys New Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Rhumbline Advisers Purchases 11,010 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
(NRIX) Long Term Investment Analysis - Stock Traders Daily
Primecap Management Co. CA Grows Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Nurix Therapeutics stock soars to 52-week high of $26.25 By Investing.com - Investing.com Australia
NRIX Stock Sees Surge of Approximately 4.08% in Last Five Days - Knox Daily
Nurix Therapeutics stock soars to 52-week high of $26.25 By Investing.com - Investing.com Canada
Nurix Therapeutics stock soars to 52-week high of $26.25 - Investing.com
Nurix Therapeutics (NASDAQ:NRIX) Reaches New 1-Year High at $26.26 - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Sets New 52-Week High at $26.26 - Defense World
Nurix Therapeutics (NASDAQ:NRIX) Shares Up 4.5% - Defense World
Financial Analysis: Nurix Therapeutics Inc (NRIX)’s Ratios Unveil Key Insights - The Dwinnex
Nurix Therapeutics Inc (NRIX) is looking forward to a strong quarter - SETE News
Arizona State Retirement System Buys Shares of 14,114 Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Checking in on Nurix Therapeutics Inc (NRIX) after recent insiders movement - Knox Daily
Nurix Therapeutics Inc’s results are impressive - US Post News
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by Quest Partners LLC - Defense World
Nurix Therapeutics (NASDAQ:NRIX) Trading 4.5% Higher - MarketBeat
TD Asset Management Inc Buys New Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
TD Asset Management Inc Invests $593,000 in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Acadian Asset Management LLC Has $2.41 Million Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Acadian Asset Management LLC Has $2.41 Million Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Los Angeles Capital Management LLC Trims Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Bank of New York Mellon Corp Purchases 49,918 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Nurix Therapeutics Inc (NRIX) may enjoy gains as insiders got busy in the recent days - Knox Daily
Nurix Therapeutics Inc (NRIX) receives an Outperform rating from Robert W. Baird - Knox Daily
Candriam S.C.A. Has $24.30 Million Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Candriam S.C.A. Boosts Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Robert W. Baird Initiates Coverage on Nurix Therapeutics (NASDAQ:NRIX) - Defense World
Nurix Therapeutics Inc Stock (NRIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):